Neuraxis

Neuraxis Enterprise Value

The Enterprise Value (EV) of Neuraxis (NRXS) as of Nov 22, 2026 is 47.76 M USD. In the previous year, Enterprise Value (EV) was 49.08 M USD — a change of -2.70% (lower).

Enterprise Value

47.76 MUSD

YoY

-2.70%

Last updated:

Enterprise Value (EV) of Neuraxis is 2025 47.76 M USD. Enterprise Value (EV) of Neuraxis was 2024 49.08 M USD. It decreases by -2.70% lower compared to the previous year.

The Neuraxis Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2020
50.72 M USD
Jan 1, 2021
52.42 M USD
Jan 1, 2022
52.65 M USD
Jan 1, 2023
52.45 M USD
Jan 1, 2024
49.08 M USD
Jan 1, 2025
47.76 M USD
The Neuraxis Enterprise Value history
YEAREnterprise ValueYoY
47.76 MUSD-2.70%
49.08 MUSD-6.42%
52.45 MUSD-0.38%
52.65 MUSD+0.43%
52.42 MUSD+3.36%
50.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Enterprise Value (EV) of Neuraxis is 47.76 M USD in 2025.

Enterprise Value (EV) of Neuraxis changed from 49.08 M USD to 47.76 M USD, representing a -2.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Neuraxis since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Neuraxis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuraxis

All Key Metrics — Neuraxis